Study Summary
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Autologous CAR-T cellsBIOLOGICAL
D0: CAR-T cells will be infused intravenously.
FludarabineDRUG
D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.
CyclophosphamideDRUG
D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The Affiliated People's Hospital of Ningbo University | Ningbo | Zhejiang | China |